Chronic administration of lipopolysaccharide and proteases induces periodontal inflammation and hepatic steatosis in rats

Journal of Periodontology

Volumn 78, Issue 10, 2007, Pages 1999-2006

  Tomofuji, Takaaki ^a   Ekuni, Daisuke ^a   Yamanaka, Reiko ^a   Kusano, Hiroki ^a   Azuma, Tetsuji ^a   Sanbe, Toshihiro ^a   Tamaki, Naofumi ^a   Yamamoto, Tatsuo ^a   Watanabe, Tatsuo ^a   Miyauchi, Mutsumi ^b   Takata, Takashi ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Animals; Fatty liver; Hepatic steatosis; Lipopolysaccharides; Periodontitis

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8-HYDROXY-2'-DEOXYGUANOSINE; DEOXYGUANOSINE; DRUG DERIVATIVE; LIPOPOLYSACCHARIDE; MITOCHONDRIAL DNA; PEPTIDE HYDROLASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DNA FRAGMENTATION; FATTY LIVER; LIVER MITOCHONDRION; MALE; METABOLISM; PERIODONTITIS; RAT; WISTAR RAT;

ANIMALS; DEOXYGUANOSINE; DNA FRAGMENTATION; DNA, MITOCHONDRIAL; FATTY LIVER; LIPOPOLYSACCHARIDES; MALE; MITOCHONDRIA, LIVER; PEPTIDE HYDROLASES; PERIODONTITIS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35648939246     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2007.070056     Document Type: Article

References (37)

1. Williams RC. Periodontal disease. N Engl J Med 1990; 322:373-382.
2. Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev 2000;13:547-558.
3. Cutler CW, Iacopino AM. Periodontal disease: Links with serum lipid/triglyceride levels? Review and new data. J Int Acad Periodontol 2003;5:47-51.
4. Chun YH, Chun KR, Olguin D, Wang HL. Biological foundation for periodontitis as a potential risk factor for atherosclerosis. J Periodontal Res 2005;40:87-95.
5. Georgiou TO, Marshall RI, Bartold PM. Prevalence of systemic diseases in Brisbane general and periodontal practice patients. Aust Dent J 2004;49:177-184.
6. Saito T, Shimazaki Y, Koga T, Tsuzuki M, Ohshima A. Relationship between periodontitis and hepatic condition in Japanese women. J Int Acad Periodontol 2006; 8:89-95.
7. Beck JD, Pankow J, Tyroler HA, Offenbacher S. Dental infections and atherosclerosis. Am Heart J 1999; 138:S528-533.
8. Nishimura F, Iwamoto Y, Mineshiba J, Shimizu A, Soga Y, Murayama Y. Periodontal disease and diabetes mellitus: The role of tumor necrosis factor-α in a 2-way relationship. J Periodontol 2003;74:97-102.
9. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. Lab Invest 1976;34:235-249.
10. Pussinen PJ, Vilkuna-Rautiainen T, Alfthan G, et al. Severe periodontitis enhances macrophage activation via increased serum lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004;24:2174-2180.
11. Tracey KJ, Fong T, Hesse DG, et al. Anti-cachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
12. Chan EL, Murphy JT. Reactive oxygen species mediate endotoxin-induced human dermal endothelial NF-kappa B activation. J Surg Res 2003;111:120-126.
13. Tsuji K, Kwon AH, Yoshida H, et al. Free radical scavenger (edaravone) prevents endotoxin-induced liver injury after partial hepatectomy in rats. J Hepatol 2005;42:94-101.
14. Ekuni D, Tomofuji T, Yamanaka R, Tachibana K, Yamamoto T, Watanabe T. Initial apical migration of junctional epithelium in rats following application of lipopolysaccharide and proteases. J Periodontal 2005; 76:43-48.
15. Hayashi I, Morishita Y, Imai K, Nakamura M, Nakachi K, Hayashi T. High-throughput spectrophotometric assay of reactive oxygen species in serum. Mutat Res 2007; 631:55-61.
16. Nakayama H, Enzan H, Yamamoto M, Miyazaki E, Yasui W. High molecular weight caldesmon positive stromal cells in the capsule of hepatocellular carcinomas. J Clin Pathol 2004;57:776-777.
17. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119: 493-501.
18. Uesugi T, Froh M, Arteel GE, et al. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002;168:2963-2969.
19. Kang MH, Naito M, Tsujihara N, Osawa T. Sesamolin inhibits lipid peroxidation in rat liver and kidney. J Nutr 1998;128:1018-1022.
20. Dumitrescu AL, Abd-El-Aleem S, Morales-Aza B, Donaldson LF. A model of periodontitis in the rat: Effect of lipopolysaccharide on bone resorption, osteoclast activity, and local peptidergic innervation. J Clin Periodontol 2004;31:596-603.
21. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
22. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33.
23. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37:56-62.
24. Enomoto N, Takei Y, Yamashima S, Ikejima K, Kitamura T, Sato N. Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization. Alcohol Clin Exp Res 2005;29:216S-219S.
25. Ekuni D, Yamamoto T, Yamanaka R, Tachibana K, Watanabe T. Proteases augment the effects of lipopolysaccharide in rat gingiva. J Periodontal Res 2003; 38:591-596.
26. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-1719.
27. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-674.
28. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:850-855.
29. Loguercio C, De Girolamo V, de Sio I, et al. Nonalcoholic fatty liver disease in an area of southern Italy: Main clinical, histological, and pathophysiological aspects. J Hepatol 2001;35:568-574.
30. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38:32-38.
31. Zhang C, Walker LM, Hinson JA, Mayeux PR. Oxidant stress in rat liver after lipopolysaccharide administration: Effect of inducible nitric-oxide synthase inhibition. J Pharmacol Exp Ther 2000;293:968-972.
32. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor a in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48:206-211.
33. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: Lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-687.
34. Schwartz J, Stinson FL, Parker RB. The passage of tritiated bacterial endotoxin across intact gingival crevicular epithelium. J Periodontol 1972;43:270-276.
35. Zhou Z, Wang L, Song Z, Saari JT, McClain CJ, Kang YJ. Abrogation of nuclear factor-κB activation is involved in zinc inhibition of lipopolysaccharide-induced tumor necrosis factor-a production and liver injury. Am J Pathol 2004;164:1547-1556.
36. Suliburk JW, Gonzalez EA, Kennison SD, Helmer KS, Mercer DW. Differential effects of anesthetics on endotoxin-induced liver injury. J Trauma 2005;58:711-716.
37. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in human in vivo. Arthritis Rheum 1992;35:982-983.